IP Library › Granted Patent US 9,518,042
Granted Patent B2
US 9,518,042 · App. 15/013,675 · Granted Dec 13, 2016

Nitrogen-containing heterocyclic compound

Inventors: Masami Yamada (Kanagawa, JP); Shinkichi Suzuki (Kanagawa, JP); Takahiro Sugimoto (Kanagawa, JP); Minoru Nakamura (Kanagawa, JP); Hiroki Sakamoto (Kanagawa, JP); Makoto Kamata (Kanagawa, JP)
Assignee: Takeda Pharmaceutical Company Limited
C07D401/06C07D209/46C07D401/10C07D401/14C07D403/04C07D403/10C07D405/04C07D405/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,518,042
App. No.
15/013,675
Granted
Dec 13, 2016
Kind
B2
Abstract

The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.

Claims (2)

1. 2-((1S,2S)-2-Hydroxycyclohexyl)-4,5-dimethyl-6-((6-methylpyridin-3-yl)methyl)isoindolin-1-one, or a salt thereof.

2. A medicament comprising 2-((1S,2S)-2-hydroxycyclohexyl)-4,5-dimethyl-6-((6-methylpyridin-3-yl)methyl)isoindolin-1-one or a salt thereof, and a pharmaceutically acceptable carrier.

Priority Claims (1)
JP 2014-089585 · Apr 23, 2014 · national
Continuity (2)
Continuation 14693342 · Apr 22, 2015
Related Publication 20160152598A1 · Jun 2, 2016